CN111587248A - Erbb受体抑制剂 - Google Patents

Erbb受体抑制剂 Download PDF

Info

Publication number
CN111587248A
CN111587248A CN201980006431.XA CN201980006431A CN111587248A CN 111587248 A CN111587248 A CN 111587248A CN 201980006431 A CN201980006431 A CN 201980006431A CN 111587248 A CN111587248 A CN 111587248A
Authority
CN
China
Prior art keywords
compound
alkyl
halogen
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980006431.XA
Other languages
English (en)
Chinese (zh)
Inventor
李正涛
钟卫
王家秉
曾庆北
徐汉忠
杨振帆
张小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizal Jiangsu Pharmaceutical Co Ltd
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Priority to CN202010657663.6A priority Critical patent/CN112266384B/zh
Priority to CN202010657654.7A priority patent/CN111662289A/zh
Priority to CN202010656946.9A priority patent/CN111747953B/zh
Publication of CN111587248A publication Critical patent/CN111587248A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980006431.XA 2018-05-08 2019-05-08 Erbb受体抑制剂 Pending CN111587248A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202010657663.6A CN112266384B (zh) 2018-05-08 2019-05-08 ErbB受体抑制剂
CN202010657654.7A CN111662289A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN202010656946.9A CN111747953B (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018085998 2018-05-08
CNPCT/CN2018/085998 2018-05-08
PCT/CN2019/085949 WO2019214634A1 (en) 2018-05-08 2019-05-08 Erbb receptor inhibitors

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202010657663.6A Division CN112266384B (zh) 2018-05-08 2019-05-08 ErbB受体抑制剂
CN202010656946.9A Division CN111747953B (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN202010657654.7A Division CN111662289A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂

Publications (1)

Publication Number Publication Date
CN111587248A true CN111587248A (zh) 2020-08-25

Family

ID=68467752

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201980006431.XA Pending CN111587248A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN202010656946.9A Active CN111747953B (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN202010657663.6A Active CN112266384B (zh) 2018-05-08 2019-05-08 ErbB受体抑制剂
CN202010657654.7A Pending CN111662289A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202010656946.9A Active CN111747953B (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN202010657663.6A Active CN112266384B (zh) 2018-05-08 2019-05-08 ErbB受体抑制剂
CN202010657654.7A Pending CN111662289A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂

Country Status (14)

Country Link
US (2) US10822334B2 (enExample)
EP (2) EP3814341B1 (enExample)
JP (2) JP7540953B2 (enExample)
KR (1) KR102806778B1 (enExample)
CN (4) CN111587248A (enExample)
AR (1) AR117424A1 (enExample)
AU (1) AU2019267959B2 (enExample)
CA (1) CA3099315A1 (enExample)
DK (1) DK3814341T3 (enExample)
ES (1) ES2977196T3 (enExample)
MX (2) MX2020011868A (enExample)
PT (1) PT3814341T (enExample)
TW (2) TWI811358B (enExample)
WO (1) WO2019214634A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114262327A (zh) * 2021-12-30 2022-04-01 武汉九州钰民医药科技有限公司 一种her2小分子抑制剂图卡替尼的制备工艺
CN114671867A (zh) * 2022-03-15 2022-06-28 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法
CN116102491A (zh) * 2023-02-17 2023-05-12 浙江晖石药业有限公司 一种利用连续流技术进行金属催化偶联的应用
CN117534669A (zh) * 2023-11-01 2024-02-09 上海凌凯医药科技有限公司 五元氮杂环并吡啶醇的制备方法
CN117658818A (zh) * 2023-11-03 2024-03-08 江西巍华化学有限公司 一种4-氟-3-硝基三氟甲苯的制备方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196622A1 (zh) * 2018-04-09 2019-10-17 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑
HRP20240293T1 (hr) 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva
AR117788A1 (es) * 2019-01-14 2021-08-25 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
TWI879751B (zh) * 2020-03-23 2025-04-11 印度商皮埃企業有限公司 3-被取代的苯基脒化合物及其製備和用途
KR20230167009A (ko) * 2020-10-05 2023-12-07 다나-파버 캔서 인스티튜트 인크. Her2에 대한 강력하고 선택적인 억제제
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CR20240163A (es) * 2021-10-20 2024-06-12 Hoffmann La Roche Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas
US20250206760A1 (en) * 2022-03-28 2025-06-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
JPWO2024043252A1 (enExample) 2022-08-24 2024-02-29
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
CN116903615A (zh) * 2023-06-21 2023-10-20 江苏丽源医药有限公司 一种妥卡替尼及其中间体的制备方法
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
CN119320383A (zh) * 2023-09-05 2025-01-17 北京鞍石生物科技股份有限公司 含氮杂芳基化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585754A (zh) * 2001-11-03 2005-02-23 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
CN111747953B (zh) * 2018-05-08 2021-05-07 迪哲(江苏)医药股份有限公司 Erbb受体抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
ES2354457T3 (es) * 2005-09-20 2011-03-15 Astrazeneca Ab Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585754A (zh) * 2001-11-03 2005-02-23 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
CN111747953B (zh) * 2018-05-08 2021-05-07 迪哲(江苏)医药股份有限公司 Erbb受体抑制剂
CN112266384B (zh) * 2018-05-08 2022-09-23 迪哲(江苏)医药股份有限公司 ErbB受体抑制剂

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114262327A (zh) * 2021-12-30 2022-04-01 武汉九州钰民医药科技有限公司 一种her2小分子抑制剂图卡替尼的制备工艺
CN114671867A (zh) * 2022-03-15 2022-06-28 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法
CN114671867B (zh) * 2022-03-15 2023-09-19 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法
CN116102491A (zh) * 2023-02-17 2023-05-12 浙江晖石药业有限公司 一种利用连续流技术进行金属催化偶联的应用
CN117534669A (zh) * 2023-11-01 2024-02-09 上海凌凯医药科技有限公司 五元氮杂环并吡啶醇的制备方法
CN117658818A (zh) * 2023-11-03 2024-03-08 江西巍华化学有限公司 一种4-氟-3-硝基三氟甲苯的制备方法

Also Published As

Publication number Publication date
CN111747953B (zh) 2021-05-07
CA3099315A1 (en) 2019-11-14
TW202015690A (zh) 2020-05-01
KR20210013071A (ko) 2021-02-03
AU2019267959A1 (en) 2020-11-26
AU2019267959B2 (en) 2024-06-06
US20200317669A1 (en) 2020-10-08
TWI811358B (zh) 2023-08-11
EP3814341A4 (en) 2022-01-05
BR112020022829A2 (pt) 2021-02-02
CN112266384A (zh) 2021-01-26
CN111662289A (zh) 2020-09-15
AR117424A1 (es) 2021-08-04
EP3814341A1 (en) 2021-05-05
PT3814341T (pt) 2024-04-11
TW202344253A (zh) 2023-11-16
ES2977196T3 (es) 2024-08-20
EP4410291A3 (en) 2024-08-14
EP3814341B1 (en) 2024-03-20
CN111747953A (zh) 2020-10-09
CN112266384B (zh) 2022-09-23
JP2024050653A (ja) 2024-04-10
US11447492B2 (en) 2022-09-20
JP2021523159A (ja) 2021-09-02
US20210009587A1 (en) 2021-01-14
WO2019214634A1 (en) 2019-11-14
KR102806778B1 (ko) 2025-05-12
US10822334B2 (en) 2020-11-03
EP4410291A2 (en) 2024-08-07
TWI858848B (zh) 2024-10-11
JP7810734B2 (ja) 2026-02-03
MX2020011868A (es) 2021-02-26
JP7540953B2 (ja) 2024-08-27
DK3814341T3 (da) 2024-04-22
MX2023008954A (es) 2023-08-18

Similar Documents

Publication Publication Date Title
CN112266384B (zh) ErbB受体抑制剂
CN116848120B (zh) 用于诱导g12d突变kras蛋白分解的喹唑啉化合物
US20250197424A1 (en) Quinoline compound and use thereof
WO2018143315A1 (ja) キナゾリン化合物
US20240067662A1 (en) Kras inhibitors
CN112771049B (zh) Fgfr4抑制剂及其应用
US20220411422A1 (en) Erbb receptor inhibitors
HK40045061A (en) Erbb receptor inhibitors
HK40045061B (en) Erbb receptor inhibitors
HK40037928A (en) Erbb receptor inhibitors
HK40037928B (en) Erbb receptor inhibitors
HK40028318A (en) Erbb receptor inhibitors
HK40028142A (en) Erbb receptor inhibitors
RU2810215C2 (ru) Ингибиторы рецепторов erbb
HK40114639A (en) Erbb receptor inhibitors
CN118255713B (zh) 一种萘酰胺类化合物、其制备方法及其应用
HK40046084B (en) Erbb receptor inhibitors
HK40046084A (en) Erbb receptor inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: No. 199, Liangjing Road, Zhangjiang hi tech park, Pudong New Area, Shanghai, 201203

Applicant after: Dizhe (Jiangsu) Pharmaceutical Co., Ltd

Address before: No. 199, Liangjing Road, Zhangjiang hi tech park, Pudong New Area, Shanghai, 201203

Applicant before: Dizal (Jiangsu) Pharmaceutical Co.,Ltd.

CB02 Change of applicant information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40028142

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination